We don’t follow footsteps. We create the path.

Employees in the Spark Therapeutics office

Spark stands with the Black community against racism and social injustice.

A statement from our CEO, Jeff Marrazzo.
Read now

News & events

Spark Therapeutics Announces Updated Data on SPK-8011 Updated data presented on Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A at ISTH 2020

Read More read more

Gene Therapy Research Published in Nature Medicine Study demonstrates role of IdeS in enabling gene therapy in presence of neutralizing anti-AAV antibodies

Read More read more

Spark Therapeutics Wins Prix Galien USA Award The Galien Foundation has awarded Spark Therapeutics with the prestigious 2019 Prix Galien USA Award for "Best Biotechnology Product"

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

Learn More